Request an invite

Yescarta: how long were the pivotal tox studies?

axicabtagene ciloleucel · CD19 CAR-T
Longest pivotal study
30 weeks
“Some mice were followed out to Day 209. The publication reported no overt toxicity, but normal B cells were decreased (i.e., B cell aplasia).”
✓ VerifiedFDA pharmacology/toxicology review, p. 16Source ↗
Pivotal GLP studies
No toxicology studies; published surrogate CAR-T study in lymphodepleted syngeneic tumor-bearing mice (Kochenderfer 2010)
“No toxicology studies with KTE-C19 were conducted.”
✓ VerifiedFDA pharmacology/toxicology review, p. 16Source ↗
Route in tox
Intravenous (after total body irradiation lymphodepletion in mice)
“Following intravenous injection of murine T cells expressing the anti-murine CD19 CAR into the mice, tumors were eliminated (i.e., lymphoma cells were undetectable) and animal survival was extended.”
✓ VerifiedFDA pharmacology/toxicology review, p. 3Source ↗

Same question, other cell therapies

Abecma

idecabtagene vicleucel · BCMA CAR-T
12 weeks

Alofisel

darvadstrocel · Allogeneic adipose MSC
26 weeks

Amtagvi

lifileucel · TIL therapy
0 (no in vivo tox study)

Aucatzyl

obecabtagene autoleucel · CD19 CAR-T
2 weeks

Breyanzi

lisocabtagene maraleucel · CD19 CAR-T
14 weeks

Carvykti

ciltacabtagene autoleucel · BCMA CAR-T
14 weeks

ChondroCelect

characterised viable autologous cartilage cells · Autologous chondrocytes
53 weeks

Ebvallo

tabelecleucel · EBV-specific allogeneic T cells
20 weeks

Encelto

revakinagene taroretcel · CNTF (encapsulated RPE cell implant)
26 weeks

Gintuit

allogeneic cultured keratinocytes and fibroblasts in bovine collagen · Allogeneic keratinocytes + fibroblasts
52 weeks

Holoclar

autologous corneal epithelial cells containing limbal stem cells · Autologous limbal stem cells
0 (no in vivo tox study)

Kymriah

tisagenlecleucel · CD19 CAR-T
31 weeks

Lantidra

donislecel · Allogeneic pancreatic islets
0 (no in vivo tox study)

MACI

autologous cultured chondrocytes on porcine collagen membrane · Autologous chondrocytes
53 weeks

Omisirge

omidubicel · Expanded cord blood HPC
12 weeks

Provenge

sipuleucel-T · PAP-GM-CSF (autologous APC)
6 weeks

Rethymic

allogeneic processed thymus tissue · Allogeneic thymus tissue
39 weeks

Ryoncil

remestemcel-L · Allogeneic BM-MSC
26 weeks

Spherox

spheroids of autologous matrix-associated chondrocytes · Autologous chondrocyte spheroids
39 weeks

StrataGraft

allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen · Allogeneic keratinocytes + fibroblasts
20 weeks

Tecartus

brexucabtagene autoleucel · CD19 CAR-T
30 weeks

Tecelra

afamitresgene autoleucel · MAGE-A4 TCR-T
0 (no in vivo tox study)

Zalmoxis

allogeneic T cells modified with HSV-TK / dLNGFR (nalotimagene carmaleucel) · HSV-TK suicide-gene T cells
3 weeks

Zemcelpro

dorocubicel · UM171-expanded cord blood CD34+
28 weeks

Laviv

azficel-T · Autologous fibroblasts
Not stated in public reviews

Tregzi

allogeneic Treg immunotherapy with HSPC and T cells (Orca-T) · Allogeneic Treg + HSPC + Tcon
Not stated in public reviews

Summary across all 27 cell therapies →